# Sisu Global Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sisu-global-health

- Industry: Medical Devices & Equipment
- Headquarters: Baltimore, US
- Website: www.sisuglobal.health
- Total disclosed funding: $2.3M
- Latest round: Seed (Jul 30, 2018)
- Investors on record: 8

## About

Sisu Global Health Inc. is a medical technology company focused on innovative solutions to address blood transfusion challenges in resource-constrained environments, enhancing patient care during critical medical situations.Sisu Global Health Inc. specializes in developing medical devices for blood transfusion. The company was founded by Carolyn Yarina and Gillian Henker, with Carolyn Yarina currently serving as CEO. Based in Baltimore, US, Sisu has engaged in 4 investment deals, with the most recent funding event occurring on October 23, 2023, where they raised USD 100,000 from Maryland Technology Development Corporation. This amount represents the total raised by the company to date.Sisu Global Health primarily offers the Hemafuse, a handheld autotransfusion device that allows clinicians to salvage, filter, and re-transfuse blood from patients experiencing internal bleeding. The Hemafuse addresses significant challenges caused by the global shortage of donor blood, estimated at 100 million units annually. This device enables immediate access to blood transfusions during various types of surgeries, including trauma, obstetric, general, and orthopedic surgeries. The Hemafuse is utilized in countries such as Kenya, Ghana, and India, serving military medical personnel, veterinarians, and healthcare providers in resource-constrained settings.Sisu Global Health generates revenue through direct sales of the Hemafuse device to hospitals and medical institutions in challenging environments. The company primarily engages in B2B transactions, where healthcare organizations purchase units to improve their surgical capabilities. Partnerships with non-profit organizations and government agencies may also facilitate subsidized sales of the Hemafuse to clinics in underserved areas. Pricing structures are aligned with healthcare procurement processes to provide cost-effective solutions for critical medical needs.In October 2023, Sisu Global Health Inc. secured USD 100,000 in venture funding to further develop its product. The company is focused on enhancing the Hemafuse and exploring new product offerings. Plans are also in place to expand into additional geographic markets, particularly targeting areas with limited access to blood transfusions. The funding will support these developmental and expansion initiatives, aiming for a broader impact in healthcare sectors where blood supply is critically needed.

## Funding rounds

- Seed, Jul 30, 2018, $1.2M — Rev1 Ventures, Women's Angel Investor Network, Rise of the Rest, Catalio Capital Management, Belle Impact Fund
- Seed, Sep 7, 2016, $1.1M — Camden Partners, Abell Foundation, Keiretsu Capital, Rise of the Rest, Belle Impact Fund

## Investors

- Camden Partners (https://capitalatlas.ai/funds/camden-partners) — Seed
- Abell Foundation — Seed
- Keiretsu Capital (https://capitalatlas.ai/funds/keiretsu-capital) — Seed
- Rise of the Rest — Seed
- Belle Impact Fund (https://capitalatlas.ai/funds/belle-impact-fund) — Seed
- Rev1 Ventures (https://capitalatlas.ai/funds/rev1-ventures) — Seed
- Women's Angel Investor Network (https://capitalatlas.ai/funds/women-s-angel-investor-network) — Seed
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Seed